HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.

Files in This Item:
2_MolTher.pdf2.87 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/48601

Title: Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Authors: Yamada, Yuma Browse this author →KAKEN DB
Furukawa, Ryo Browse this author
Yasuzaki, Yukari Browse this author
Harashima, Hideyoshi Browse this author →KAKEN DB
Issue Date: Aug-2011
Publisher: Nature Publishing
Journal Title: Molecular therapy : the journal of the American Society of Gene Therapy
Volume: 19
Issue: 8
Start Page: 1449
End Page: 1456
Publisher DOI: 10.1038/mt.2011.99
PMID: 21694702
Abstract: Mitochondrial dysfunction is associated with a variety of human diseases including inherited mitochondrial diseases, neurodegenerative disorders, diabetes mellitus, and cancer. Effective medical therapies for mitochondrial diseases will ultimately require an optimal drug delivery system, which will likely be achieved through innovations in the nanotechnology of intracellular trafficking. To achieve efficient mitochondrial drug delivery, two independent processes, i.e., "cytoplasmic delivery through the cell membrane" and "mitochondrial delivery through the mitochondrial membrane" are required. In previous studies, we developed an octaarginine (R8) modified nano carrier for efficient cytoplasmic delivery, showing that R8-modified liposomes were internalized into cells efficiently. On the other hand, we also constructed MITO-Porter for the mitochondrial delivery of macromolecules, a liposome-based carrier that delivers cargos to mitochondria via membrane fusion. Here, we report the development of a dual function MITO-Porter (DF-MITO-Porter), based on the concept of integrating both R8-modified liposomes and MITO-Porter. We show that the DF-MITO-Porter effectively delivers exogenous macro-biomolecules into the mitochondrial matrix, and provide a demonstration of its potential use in therapies aimed at mitochondrial DNA.
Type: article
URI: http://hdl.handle.net/2115/48601
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 山田 勇磨

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University